Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03043872 · ClinicalTrials.gov registry record · Phase 3
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
A Phase 3 study of Small Cell Lung Carcinoma Extensive Disease, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 987
- Enrollment target
- 20
- Study locations
NCT03043872 is a Phase 3 study of Small Cell Lung Carcinoma Extensive Disease that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 987 participants. The trial reports 20 study locations across 17 states.
The verdict
NCT03043872, a Phase 3 study of Small Cell Lung Carcinoma Extensive Disease, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 987 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Etoposide
- DRUG Durvalumab
- DRUG Tremelimumab
Study Locations (20)
Indiana
- Research Site - Fort Wayne
- Research Site - Muncie
Kansas
- Research Site - Leawood
- Research Site - Wichita
Ohio
- Research Site - Cleveland
- Research Site - Columbus
Alabama
- Research Site - Birmingham
Arizona
- Research Site - Scottsdale
Arkansas
- Research Site - Rogers
California
- Research Site - Santa Monica
Connecticut
- Research Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 987 participants |
| Start Date | 2017-03-27 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03043872
The ClinicalTrials.gov registry entry for NCT03043872 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 987 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small Cell Lung Carcinoma Extensive Disease appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03043872 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Indiana, Kansas, Ohio.
Frequently Asked Questions
What is clinical trial NCT03043872 about?
NCT03043872 is a clinical study titled "Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)". This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with ...
What is the current status of trial NCT03043872?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 987 participants. The study started on 2017-03-27. Estimated completion is 2025-12-31.
What conditions does trial NCT03043872 study?
This clinical trial studies the following conditions: Small Cell Lung Carcinoma Extensive Disease.
What interventions are being tested in trial NCT03043872?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Etoposide (DRUG), Durvalumab (DRUG), Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT03043872?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03043872 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.